Lung protective effect of Ticagrelor in endotoxemia.
Ticagrelor
endotoxemia
lung protective effect
Journal
Journal of medicine and life
ISSN: 1844-3117
Titre abrégé: J Med Life
Pays: Romania
ID NLM: 101477617
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
04
11
2022
accepted:
03
03
2023
medline:
8
9
2023
pubmed:
7
9
2023
entrez:
7
9
2023
Statut:
ppublish
Résumé
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. This study aimed to investigate the potential protective effect of the lungs in sepsis by modulating inflammatory and oxidative stress markers. Twenty-four adult male Swiss-albino mice, aged 8-12 weeks and weighing 20-30 g, were divided into four equal groups (n=6): sham (laparotomy only), CLP (laparotomy plus cecal ligation and puncture), vehicle (DMSO administered one hour before CLP), and Ticagrelor (50 mg/kg IP administered one hour before CLP). Tissue levels of pro-inflammatory and oxidative stress markers in the lung were assessed using ELISA. F2 isoprostane levels were significantly higher in the sepsis group (p<0.05) compared to the sham group, while Ticagrelor significantly decreased the inflammatory and oxidative stress markers compared to the sepsis group. All mice in the sepsis group had considerable (p=0.05) lung tissue damage, but Ticagrelor considerably decreased lung tissue injury (p=0.05). Furthermore, Ticagrelor was found to reduce tissue cytokine levels of the lung (IL-1, TNF a, IL-6, F2 isoprostane, GPR 17, MIF) in male mice during CLP-induced polymicrobial sepsis by modulation of pro-inflammatory and oxidative stress cascade signaling pathways.
Identifiants
pubmed: 37675176
doi: 10.25122/jml-2022-0308
pii: JMedLife-16-941
pmc: PMC10478651
doi:
Substances chimiques
F2-Isoprostanes
0
Ticagrelor
GLH0314RVC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
941-947Informations de copyright
©2023 JOURNAL of MEDICINE and LIFE.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Eur J Med Res. 2021 Jul 6;26(1):70
pubmed: 34229761
Vasc Health Risk Manag. 2021 Jun 15;17:357-362
pubmed: 34163168
Nature. 2014 Oct 9;514(7521):187-92
pubmed: 25119034
J Sex Med. 2017 Feb;14(2):187-195
pubmed: 28161077
Vascul Pharmacol. 2015 Aug;71:201-7
pubmed: 25869515
Drug Res (Stuttg). 2022 Mar;72(3):156-162
pubmed: 34852366
J Cardiovasc Pharmacol Ther. 2019 Nov;24(6):509-520
pubmed: 31280622
Science. 2013 Sep 13;341(6151):1250-3
pubmed: 24031018
Virulence. 2014 Jan 1;5(1):20-6
pubmed: 24280933
J Cell Mol Med. 2014 Sep;18(9):1785-96
pubmed: 24909956
Arterioscler Thromb Vasc Biol. 2016 May;36(5):961-71
pubmed: 27055904
Autophagy. 2020 Jan;16(1):3-17
pubmed: 30951392
Clin Invest Med. 2020 Dec 27;43(4):E44-55
pubmed: 33370524
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
J Med Life. 2022 Jun;15(6):819-827
pubmed: 35928365
J Pharmacol Exp Ther. 1997 Jan;280(1):301-9
pubmed: 8996210
Toxicol Appl Pharmacol. 2016 Aug 15;305:46-54
pubmed: 27260672
Sci Adv. 2019 May 22;5(5):eaav5562
pubmed: 31131320
Cell Death Discov. 2022 Feb 14;8(1):61
pubmed: 35165294
Curr Med Sci. 2022 Jun;42(3):505-512
pubmed: 35678913
Neuroscience. 2012 Jan 27;202:42-57
pubmed: 22155652
Sci Rep. 2019 Apr 11;9(1):5936
pubmed: 30976041
Crit Care Nurs Clin North Am. 2011 Mar;23(1):41-66
pubmed: 21316567
J Am Heart Assoc. 2018 Nov 6;7(21):e009600
pubmed: 30608200
Biosci Rep. 2020 May 29;40(5):
pubmed: 32319516
Int Immunopharmacol. 2021 Feb;91:107295
pubmed: 33360086
Int Immunopharmacol. 2021 Oct;99:107914
pubmed: 34246059
Nature. 2011 Oct 16;479(7371):117-21
pubmed: 22002608
Kidney Blood Press Res. 2019;44(4):465-478
pubmed: 31230050
Platelets. 2019;30(2):199-205
pubmed: 29370574
Expert Opin Ther Pat. 2019 Feb;29(2):85-95
pubmed: 30640576
Braz J Infect Dis. 2020 Nov - Dec;24(6):552-560
pubmed: 33169675
Int J Mol Sci. 2022 Jan 13;23(2):
pubmed: 35055007